BSTITUTE ODIFIED)	FORM	PTO-1449		U. PA	S. DEPARIMENT	OF COMMERCE DENTRY OFFICE	ATTY. DOCKET NO. 06275/004001 SERIAL NO. 08/736,267						
		FORMATION ATEMENT B	V ADE	LOSURE	FED	[17]	APPLICANT Kjell G.E. Backstrom et	al					
. (I	Use se	veral she	ets		PROPERTY 17	1998 C10	FILING DATE October 24, 1996	GROUP 1817	1 =:				
-					MADEMAR	S. PATENT	DOCUMENTS						
MINER TIAL		PATENT	r NUM		I SSUE DATE		PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
	AA												
			L_	<u> </u>	FOREIGN PAT	ENT OR PUBLISHE	ED FOREIGN PATENT APPLIC	ATION					
					PUBLICATION				SUBCLASS	TRANSLATION			
		DOCUMEN'	CUMENT NUMBER		DATE	COUNTRY OR PATENT OFFICE		CLASS	SUBCLASS	YES	NO		
(749	AB	0 122 03	6		10/17/84	Europe							
PRIZ	AC	43556/93			01/04/94	Australia							
7017	AD	90/04962			05/17/90	PCT							
DA)	AE.	91/16882	?		11/14/91	PCT							
CARS	AF	91/16929	>		11/14/91	PCT							
ph)	AG	93/25198	3		12/23/93	PCT Abstract only							
PAU.	АН	94/2246	1		10/13/94	PCT							
PAD.	AI	95/0015	1		01/05/95	PCT				<u> </u>			
	L		071	ED DOC	UMENTS (Incl.	ıdina Author, T	itle, Date, Place of Pub	lication)					
		T T											
PAD	AJ	Kein	Remington's Pharmaceutical Science, 18th edn., p. 1079 (1990)										
		Longenecker et al., Effects of Sodium Taurodihydrofusidate on Nasal Absorption of Insulin in Shed								in Shee	р,		
PAN A	AK	1 1 .											
	<u> </u>	Mizgala et al.			., <u>76(5)</u> :351-355 (1987) ., Renal Handling of Phosphate, <u>Physiological Reviews</u> , <u>65(2)</u> :431-466 (1985)								
pan)	AL												
	-	Sa	lzman	et al	., Intranasal	Aerosolized In	nsulin Mixed-Meal Studie	s and Long-te	rm Use in Ty	/pe I Dia	betes,		
PAD.	AM	The	e New	Fnala	nd Journal of	Medicine, 312	: 1078-1084, 1985						
		Zi	ngg e	t al.,	Transhepatio	: Absorption an	d Biliary Excretion of I	nsulin, <u>Can.</u>	J. Physiol.	Pharmaco	<u>ol.,</u>		
PAD	AN	 			(1987)								
EXAMI	 Ner						DATE CONSIDERED						
EXAMINER: Initial citation considered. Draw line through ci							74 Apr. 1	78	considered	Includ	e copy		

Sheet ____1 (A) ___ of ___1

		•			J							Sh	eet1 (/	(1) of _	3	
UBSTITUTE FORM PTO-1449 U.S. D. KIMENT OF COMMERCE PATENT AND RAPEMARK OFFICE								U.S	D TMEN	EWARK DELICE	ATTY. DOCKET NO. SERIAL NO. 08/736,267					
	ς.	NFOR	MEN	IT I	BY	APP	LIC	JRE ANT	(O)	~;\	APPLICANT Kjell Bäckström et al					
() 37 CFR 1.	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessar)									1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	FILING DATE October 24, 1996		GROUP 1817			
37 CIR 1.									- 12	U.S. PATEN	T DOCUMENTS					
AMINER ITIAL		PATENT NUMBER							I SSUE DATE	PATENTEE		CLASS	SUBCLASS	FILING IF APPRO	DATE PRIATE	
PAO	AA	4	8	9	5	7	1	9	1/23/90	Radhakrishnar	1					
PAD	AB	5	0	0	6	3	4	3	4/9/91	Benson						
Peso	AC	5	0	1	1	6	7	8	4/30/91	30/91 Wang						
DAD	AD	5	1	2	2	3	7	6	6/16/92	6/16/92 Aliverti						
PAD.	AE	4	9	9	4	4	3	9	2/19/91	2/19/91 Longenecker						
PAD	AF	5	1	7	9	0	7	9	1/12/93	1/12/93 Hansen						
PAN	AG	5	5	1	4	6	7	0	6/7/96	6/7/96 Friedman						
PAO	АН	5	1	1	8	4	9	4	6/2/92	6/2/92 Schultz						
2007	ΑI	5	3	4	8	7	7 3	0	9/20/94	9/20/94 Greenleaf						
DAD	AJ	3	0	1	4	. 8	3 4	4	12/26/61	Thiel						
PAT	AK	4	9	6	3	3	3 6	7	1	Ecanow				<u> </u>		
			_						FOREIGN PA	TENT OR PUBLIS	SHED FOREIGN PATENT APPL	ICATION		TRANSL	ATION	
						1	PUBLICATION DATE	COUNTRY OR PATENT OFFICE		CLASS	SUBCLASS	YES	NO			
- 0 >	AL	+-	<u>_</u> _	91.	/16	038			10/31/91	PCT						
PAD PAD	AM	-		_					6/15/60	Great Brit	ain					
	AN		GB 837,465 6/15/60 Great Birta DD 261 096 A1 10/19/88 Germany						10/19/88	Germany				<u> </u>		
PAD PAD	-	+	EP 0 200 383 4/7/86 Europe						4/7/86	Europe						
PAN	AP	+	EP 0 055 041 12/3/81 Europe						12/3/81	Europe						
<u>,</u>	1	_		_		071		חחר	IMENTS (Incl	uding Author,	Title, Date, Place of P	ublication)				
	τ					011	vde.		ka (Daghlade	t), Monday, Ju	une 12, 1989, Diabetics	May Not Need T	neir Insuli	Shots.		
D40	AQ	Ruin, Sydsvenska (Dagbladet), Monday, June 12, 1989, Diabetics May Not Need Their Insulin Shots.														

		OTHER POSSESSES
	AQ	Ruin, Sydsvenska (Dagbladet), Monday, June 12, 1989, Diabetics May Not Need Their Insulin Shots.
P40		Almer et al., Diabetes Res. and Clin. Pract. 5:S163 (1988)
PAD	AR	Almer et al., Diabetes Res. and Ctim. Fracti
<u>'</u>		Björk, Acta Univ. Uppsala, Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy
TA	AS	103 (1993)
 		DATE CONSIDERED

EXAMINER

PATRICIAA. DUFF

du April 98

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

				, .	J							She	eet <u>2 (B</u>		3	
SUBSTITUTE (MODIFIED)	FORM	PTO	- 14	49				U.S	ENT AND TAL	PHANK OFFICE	ATTY. DOCKET NO. 06275/004001		SERIAL NO 08/736,26). 57 		
	11	IFOR	MEN	IT F	RY /	APPI	L I C/	ANT	6	ΑΟ' \ Ι.	APPLICANT (jell Bäckström et al.					
(STATEMENT BY APPLICANT (Use several sheets if necessary)									~ ^ 『 割 『	FILING DATE		GROUP 1817		1	
(37 CFR 1	.98(b))								∞	October 24, 1996					
									~	WT& TRADEPATENT	DOCUMENTS			FILING DA	TE	
EXAMINER INITIAL			PA	PATENT NUMBER					I SSUE DATE	PATENTEE CLASS			SUBCLASS	IF APPROPE	IATE	
PASIT	ВА	5	1	2	2	1	2	7	6/16/92	Stanley						
PAT	ВВ	4	8	4	7	2	9	8	4/11/89	Alexander						
PAD.	вс	5	2	0	0	3	9	3	4/6/93	Weiner						
PAY	BD	5	4	8	2	7	0	6	1/9/96	Igari et al.						
PAD	BE	5	1	9	2	5	4	8	3/9/93	Velasquez et a	l.					
	BF	5	2	5	4	3	3	0	10/19/93	Ganderton et a	ι.					
PAD	BG	5	-	├	0	├	╀─	6	11/9/93	Boardman et al						
	ВН	5	├-	-	├-	⊢	╁╌	8	2/22/94	Stanley et al.						
PAD	BI	5	├	├-	╀	┾╌	8	6	12/27/94	Ganderton et a	il.					
PAD		5	╀	+-	┼-	┼	+-	+-	ļ	Boyes et al.						
PAO	BJ	5	+-	+	┼	+-	╁╴	╀		Hodson et al.						
PAD	BK BL	5	+-	╀	+-	+-	3	╀	 	Smith et al.				ļ		
PAN	BM	5	╀	╁	+-	+-	+	+	1/24/95	Backstrom et a	al.					
PAO	 	+	5 4	+-	+-	4		┿	1 8/1/95	Backstrom et	al.					
PAG) BN		<u>'</u>	1						ATENT OR PUBLISH	ED FOREIGN PATENT APPLI	CATION				
									PUBLICATIO			CLASS	SUBCLASS	TRANSLA	TION	
			DOCUMENT NUMBER			R	DATE		COUNTRY OR PATENT OFFICE		30202760	YES NO				
	+				/08	1.1.6			5/29/92	PCT						
DAD	ВО				023				7/29/80	Europe						
pm		+			023				4/12/90	PCT						
PAD	BQ		WU			OT!	UE D		LIMENTS (Inc.	Luding Author, T	itle, Date, Place of Pub	olication)				
		_							Drug Deli	very to the Resp	iratory Tract Using Dry	Powder Inhal	ers, Int. J	. Pharmaceu	tics	
740	BR	-		_												
		_		10	01:	1-1	3 (neal Delivery of	Peptide and Protein Age	nts: Absorpti	on from Sol	ution and D	ry Powd	
San	ВЅ	-					et al., Intratracheal Delivery of Peptide and Protein Agents: Absorption from Solution and Dry Powde Lung, J. Pharm. Sci. 83:863-867 (1994)									
Anix		4		þ	y R	at	Lun	9,	ntroposal pi	ioavailability of	Insulin Powder Formula	tions: Effect	of Permeat	ion Enhance	er-to-	
(AS)	ВТ				Lee et al., Intranasal Bioavailability of Insulin Powder Formulations: Effect of Permeation Enhancer-to- Protein Ratio, J. Pharm Sci. 80:725-729 (1991)											
Acres				P	rot	eir	n Ra	tic	, J. Pharm :		DATE CONSIDERED					
EXAM	IINER			· ·				, ,	nu EG-4		Zu April S	28				

SUBSTITUTE FORM PTO-1449 (MODIFIED)

U.S. DE ARTHUT DE COMMERCE PATENT AND TRADEMARK OF A CE

ATTY. DOCKET NO. 06275/004001

FILING DATE

October 24, 1996

SERIAL NO. 08/736,267

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary APPLICANT Kjell Bäckström et al.

GROUP 1817

(37 CFR 1.98(b))

		OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)
		OTHER DOCUMENTS (Including Author, Titte, Date, Floor odertrin as an Absorption Enhancer in Rabbits:
		Schipper et al., Nasal Insulin Delivery with Dimethyl- β -Cyclodextrin as an Absorption Enhancer in Rabbits:
PAN	CA	Powder More Effective than Liquid Formulations, Pharm. Res. 10:682-686 (1993)
		Lee et al., Mucosal Penetration Enhancers for Facilitation of Peptide and Protein Drug Absorption,
PAY	СВ	Critical Rev. Therapeut. Drug Carrier Systems 8:91-192 (1991)
		Wearley, Recent Progress in Protein and Peptide Delivery by Noninvasive Routes, Critical Rev. Therapeut.
Day (CC	2 - 2ion Systems 8:331-394 (1991)
		Laube et al., Preliminary Study of the Efficacy of Insulin Aerosol Delivered by Oral Inhalation in Diabetic
SEC	CD	Partients IAMA 269:2106-2109 (1993)
		Dahlbäck et al., Regional Administration of Drugs to the Rabbit Respiratory Tract, Effects on Absorption,
PAI)	CE	Madising 1:222-223 (1988)
		Yoshida et al., Absorption of Insulin Delivered to Rabbit Trachea Using Aerosol Dosage Form, J. Pharma. Sci.
CARG	CF	68:670-671 (1979)
		Damasy et al., Diabetes Res. and Clin. Pract. 5:S163 (1988)
Cray	CG	
	 	Chandler et al., Nasal Absorption in Rats. II. Effect of Enhancers on Insulin Absorption and Nasal
(N)	СН	Wistology Int J. Pharmaceutics 76:61-70 (1991)
	 	Hirai et al., Effect of Surfactants on the Nasal Absorption of Insulin in Rats, Int. J. Pharmaceutics
(49)	CI	0.145-172 (1081)
	+	Gordon et al., Nasal Absorption of Insulin: Enhancement by Hydrophobic Bile Salts, Proc. Natl. Acad. Sci.
DAN	C1	02-7/10-7/23 (1085)
	-	Moses et al., Insulin Administered Intranasally as an Insulin-Bile Salt Aerosol, Diabetes 32:1040-47 (1983)
000	CK	
		Wigley et al., Insulin Across Respiratory Mucosae by Aerosol Delivery, Diabetes 20:552-556 (1971)
(M)	CL	
	-	Cutie et al., The Role of Dispersing Agents in Inhalation and Intranasal Aerosol Suspensions, Aerosol. Age
PA)	СМ	30:52-54 (1985)
	CN	
	+-	
	со	
EVAN	INER	DATE CONSIDERED Zu April 98

PATRICIA 4 DURY

Zu Agril 98

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.